Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms may ultimately control the industry’s future. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool.
The broader market context makes Oncotelic’s strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion by 2031. Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts into its PDAOAI platform. This massive dataset, encompassing decades of biomedical research, dramatically enhances the platform’s ability to identify novel drug targets, predict drug interactions, and accelerate the discovery of new therapies.
For an industry where the average cost of developing a new drug exceeds $2.6 billion and takes over a decade, such efficiencies are transformative. By leveraging AI to parse vast scientific literature, Oncotelic aims to reduce the time and cost of early-stage research, potentially bringing treatments to patients faster. The implications extend beyond Oncotelic’s pipeline; as the company refines its platform, it could license the technology to larger pharmaceutical partners, opening new revenue streams and disrupting traditional R&D models.
The integration of 28 million abstracts also positions Oncotelic as a data-rich entity in an era where data is the new currency. With a focus on oncology, the platform is tailored to address one of the most challenging and high-value therapeutic areas. Investors and industry observers are taking note, as the company continues to demonstrate that small biotech can out-innovate big pharma. For more information, the latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC.
